查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1403340

到 2030 年病毒性胃腸炎市場預測：按類型、診斷、治療、藥物、劑量、適應症、給藥途徑、配銷通路、最終用戶和地區進行的全球分析

Viral Gastroenteritis Market Forecasts to 2030 - Global Analysis By Type, Diagnosis, Treatment, Drug, Dosage, Indication, Route of Administration, Distribution Channel, End User and by Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，2023 年全球病毒性胃腸炎市場規模為 471.6 億美元，預計到 2030 年將達到 737.7 億美元，預測期內複合年成長率為 6.6%。

胃腸炎，也稱為病毒性胃腸炎，是一種引起腸道和胃部發炎的傳染性腸道疾病。主要致病病毒為輪狀病毒、腺病毒和諾羅病毒。它具有高度傳染性，通常透過受污染的食物或水或與感染者的密切接觸傳播。常見症狀包括腹瀉、嘔吐、腹部絞痛、發燒和噁心，嚴重時會導致脫水。

美國健身保健公司 Bodibio 對 33 個國家的 73,076 名成年人進行的一項調查顯示，40% 的受訪者患有功能性胃腸道疾病（功能性消化不良、大腸激躁症、功能性便秘）。包括所有變異）。

病毒附著傳播

引起胃腸炎的病毒，如輪狀病毒、諾羅病毒等，傳染性極強，是造成族群感染傳播的主要因素。病毒的傳播主要透過人與人之間的接觸、霧化嘔吐物顆粒和受污染的表面進行。此外，這種傳播性的增加導致病毒性胃腸炎的快速和廣泛爆發，特別是在擁擠的環境和人際接觸密切的社區中。

缺乏針對性的抗病毒治療

缺乏針對包括諾羅病毒在內的許多病原體的特異性抗病毒藥物，是治療病毒性胃腸炎的主要障礙。與通常使用抗生素治療的細菌感染不同，病毒性胃腸炎的支持治療主要著重於保濕和緩解症狀。此外，缺乏標靶抗病毒藥物限制了治療性介入的選擇。

疫苗研發

研究和開發針對胃腸炎病毒（尤其是諾羅病毒）的強效疫苗的生產是一個重大機會。透過更了解宿主免疫反應和病毒基因組學，可以實現疫苗開發的新方法。此外，成功的疫苗可以徹底改變預防措施，並降低胃腸炎爆發的發生率和強度。

缺乏特異性抗病毒治療

主要威脅之一是缺乏針對許多胃腸炎病毒的特異性抗病毒藥物。病毒性胃腸炎主要透過支持性護理來治療，治療性介入選擇有限。此外，由於缺乏針對性的抗病毒治療，嚴重​​病例的治療變得更加困難。

COVID-19 的影響：

病毒性胃腸炎市場受到了 COVID-19大流行的影響。隨著全球衛生保健系統專注於控制這一流行病，病毒性胃腸炎的盛行率有所不同。為了阻止 COVID-19 的傳播，人們關緊了門，保持社交距離，並改善了衛生習慣，這減少了胃腸炎病毒的傳播數量。此外，由於公眾對流感大流行的關注和資源的變化、監測活動的減少以及醫療服務的中斷，事實證明，要準確追蹤和管理胃腸炎患者很困難。

預計輪狀病毒領域在預測期內將是最大的。

由於其對全球公共衛生的廣泛影響，輪狀病毒在病毒性胃腸炎中佔據主導地位，佔據最大的市場佔有率。此外，眾所周知，輪狀病毒感染疾病是嚴重腹瀉的主要原因，尤其是幼兒。它還顯著增加了與胃腸炎相關的發病率和死亡率的整體負擔。該病毒具有高度傳染性，並適應多種環境，因此經常在多種環境中發現，包括兒童保育設施和醫療保健條件較差的地區。

預計門診護理中心產業在預測期內將經歷最高的複合年成長率。

複合年成長率最高的門診護理中心產業在醫療保健產業的重要性日益增加。這些中心對於醫療保健服務的轉型至關重要，因為它們專門提供門診病人服務、診斷和預防性護理。此外，推動門診護理成長的是向以患者為中心的模式的轉變以及對負擔得起且易於獲得的醫療保健選擇的需求不斷成長。

佔有率最大的地區

北美繼續佔據最大的市場佔有率。該地區的優勢可以歸因於多種因素的結合，包括先進的醫療基礎設施、大量的研發投資、有彈性的法規結構以及不斷成長的醫療支出。而美國憑藉其先進的醫療技術、成熟的製藥工業和完善的醫療保健體系，尤其成為北美醫療保健市場的主要動力。

複合年成長率最高的地區：

預計歐洲地區在預測期內複合年成長率最高。歐洲憑藉其完善的醫療基礎設施、高標準的醫學研究和創新以及廣泛的醫療保健系統，一直在全球醫療保健市場佔有很大佔有率。此外，人口高齡化、慢性病發病率以及對可獲得的高品質醫療保健的重視正在支持歐洲在全球醫療保健領域的持續崛起和影響力。

免費客製化服務：

訂閱此報告的客戶可以存取以下免費自訂選項之一：

  • 公司簡介
    • 其他市場參與者的綜合分析（最多 3 家公司）
    • 主要企業SWOT分析（最多3家企業）
  • 區域分割
    • 根據客戶興趣對主要國家的市場估計、預測和複合年成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章執行摘要

第2章 前言

  • 概述
  • 相關利益者
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 資料分析
    • 資料檢驗
    • 研究途徑
  • 調查來源
    • 主要調查來源
    • 二次調查來源
    • 先決條件

第3章市場趨勢分析

  • 促進因素
  • 抑制因素
  • 機會
  • 威脅
  • 最終用戶分析
  • 新興市場
  • 新型冠狀病毒感染疾病（COVID-19）的影響

第4章波特五力分析

  • 供應商的議價能力
  • 買方議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間的敵對關係

第5章全球病毒性胃腸炎市場：依類型

  • 諾羅病毒
  • 輪狀病毒
  • 星狀病毒
  • 腸腺病毒
  • 其他類型

第6章全球病毒性胃腸炎市場：依診斷

  • 體檢
  • 快速糞便檢驗

第7章全球病毒性胃腸炎市場：依治療分類

  • 靜脈輸液
  • 運動抑制劑
  • 電解質
  • 止吐藥
  • 止瀉藥
  • 其他治療

第8章全球病毒性胃腸炎市場：依藥物分類

  • 抗生素
  • 制酸劑
  • 瀉藥
  • 化療藥物
  • 其他藥品

第9章全球病毒性胃腸炎市場：依藥物分類

  • 錠劑
  • 注射
  • 其他藥物

第10章全球病毒性胃腸炎市場：依適應症分類

  • 水樣腹瀉
  • 嘔吐
  • 腹痛和痙攣
  • 暈眩的
  • 腹瀉
  • 噁心
  • 嘔吐
  • 頭痛
  • 寒冷的
  • 食慾下降
  • 熱
  • 關節僵硬
  • 流汗
  • 肌肉疼痛
  • 減重
  • 其他適應症

第11章全球病毒性胃腸炎市場：依給藥途徑

  • 口服
  • 靜脈
  • 其他

第12章全球病毒性胃腸炎市場：按配銷通路

  • 醫院藥房
  • 零售藥房
  • 線上藥房

第13章全球病毒性胃腸炎市場：依最終用戶分類

  • 診斷中心
  • 門診治療中心
  • 其他最終用戶

第14章全球病毒性胃腸炎市場：按地區

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲

第15章 主要進展

  • 合約、夥伴關係、協作和合資企業
  • 收購和合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第16章 公司簡介

  • Bausch Health Companies Inc.
  • Abbott
  • Cipla Inc.
  • Sanofi
  • Bayer AG
  • Allergan
  • Dr. Reddy's Laboratories Ltd.
  • Johnson & Johnson Private Ltd.
  • Takeda Pharmaceutical Company Ltd.
  • Valeant Pharmaceuticals
  • Astellas Pharma Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Sun Pharmaceutical Industries Ltd.
  • Aurobindo Pharma
  • Eli Lilly and Company
  • Novartis AG
  • Janssen Biotech Inc.
  • Mylan NV
Product Code: SMRC24565

According to Stratistics MRC, the Global Viral Gastroenteritis Market is accounted for $47.16 billion in 2023 and is expected to reach $73.77 billion by 2030 growing at a CAGR of 6.6% during the forecast period. The stomach flu, also referred to as viral gastroenteritis, is an infectious intestinal disease that causes inflammation in the intestines and stomach. The rotavirus, adenovirus, and norovirus are the main viruses that cause it. Being highly contagious, the illness usually spreads through contaminated food, water, or intimate contact with an infected person. Moreover, diarrhea, vomiting, cramps in the abdomen, fever, and nausea are common symptoms; in severe cases, dehydration results.

According to a survey report across 33 countries among 73,076 adults by Bodibio, a US-based fitness and wellness company, 40% of those surveyed had a functional gastrointestinal disorder, including all the variations of functional dyspepsia, irritable bowel syndrome, functional constipation, and others.

Market Dynamics:

Driver:

Spread of viral adherence

The highly contagious nature of viruses that cause gastroenteritis, like rotavirus and norovirus, is a major factor in the spread of outbreaks. Viral transmission occurs mainly through person-to-person contact, aerosolized vomit particles, and contaminated surfaces. Additionally, this increased transmissibility, particularly in crowded environments and communities with close interpersonal contact, plays a role in the quick and widespread occurrence of viral gastroenteritis.

Restraint:

Lack of targeted antiviral treatment

The lack of specific antiviral drugs for many of the causative agents, including norovirus, is a significant barrier to treating viral gastroenteritis. In contrast to bacterial infections, which are typically treated with antibiotics, supportive care for viral gastroenteritis primarily focuses on rehydration and symptom relief. Furthermore, therapeutic intervention options are limited due to the absence of targeted antiviral drugs.

Opportunity:

Development and research on vaccines

Research and development efforts aimed at producing potent vaccines against gastroenteritis viruses, particularly noroviruses, present a substantial opportunity. Novel approaches to the development of vaccines could be made possible by growing comprehension of host immune responses and viral genomics. Moreover, a successful vaccine could transform prophylactic measures and lessen the incidence and intensity of gastroenteritis outbreaks.

Threat:

Absence of particularized antiviral therapy

One major threat is the lack of specific antiviral drugs for many gastroenteritis viruses. Viral gastroenteritis is primarily treated with supportive care, with limited options for therapeutic interventions, unlike bacterial infections, which are frequently treated with targeted antibiotics. Additionally, the management of severe cases is made more difficult by the absence of a targeted antiviral treatment.

COVID-19 Impact:

The market for viral gastroenteritis has been affected by the COVID-19 pandemic. As global healthcare systems have primarily concentrated on controlling the pandemic, there have been variations in the prevalence of viral gastroenteritis cases. In an attempt to stop the spread of COVID-19, lockdowns, social distancing measures, and improved hygiene practices have all somewhat reduced the number of gastroenteritis viruses that are being transmitted. Moreover, accurately tracking and managing gastroenteritis cases has proven difficult, due to changes in public attention and resources towards the pandemic, decreased surveillance efforts, and disruptions in healthcare services.

The Rotavirus segment is expected to be the largest during the forecast period

Due to the widespread influence on public health worldwide, the rotavirus segment is a dominant force in the viral gastroenteritis landscape, possessing the largest market share. Additionally, rotavirus infections are well known for being a major cause of severe diarrhea, particularly in young children. They also significantly increase the overall burden of morbidity and mortality associated with gastroenteritis. Due to the virus's high contagiousness and adaptability to different environments, it is frequently found in a wide range of settings, including childcare facilities and areas with poor access to healthcare.

The Ambulatory Care Centers segment is expected to have the highest CAGR during the forecast period

With the highest CAGR, the ambulatory care center segment is becoming more and more important in the healthcare sector. These centers are essential to the transformation of healthcare delivery because they are dedicated to providing outpatient services, diagnostics, and preventive care. Furthermore, the growth of ambulatory care has been driven by a shift towards patient-centric models and an increasing demand for affordable and easily accessible healthcare options.

Region with largest share:

North America has continuously held the largest market share. The region's prominence is ascribed to a confluence of factors such as sophisticated healthcare infrastructure, significant investments in research and development, a resilient regulatory framework, and elevated healthcare spending. However, with its sophisticated medical technology, firmly established pharmaceutical industry, and extensive healthcare system, the United States in particular stands out as a major driver of the North American healthcare market.

Region with highest CAGR:

During the forecast period, the European region is expected to have the highest CAGR. Europe consistently holds a sizable share of the global healthcare market thanks to its well-established healthcare infrastructure, high standards for medical research and innovation, and extensive healthcare systems. Moreover, the aging population, the frequency of chronic illnesses, and the emphasis on accessible and high-quality healthcare all support Europe's continued rise and clout in the world healthcare arena.

Key players in the market:

Some of the key players in Viral Gastroenteritis market include Bausch Health Companies Inc., Abbott, Cipla Inc., Sanofi, Bayer AG, Allerga, Dr. Reddy's Laboratories Ltd, Johnson & Johnson Private Ltd., Takeda Pharmaceutical Company Ltd., Valeant Pharmaceuticals, Astellas Pharma Inc., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma, Eli Lilly and Company, Novartis AG, Janssen Biotech Inc. and Mylan N.V.

Key Developments:

In September 2023, Bausch + Lomb Corporation, a subsidiary of Bausch Health Companies Inc., announced it has completed its acquisition of XIIDRA® 5%, a non-steroid eye drop specifically approved to treat the signs and symptoms of dry eye disease focusing on inflammation associated with dry eye, and certain other ophthalmology assets.

In September 2023, Abbott has entered a definitive agreement for the acquisition of Bigfoot Biomedical, which develops smart insulin management systems for individuals with diabetes. Together, the companies have worked on connected diabetes solutions since 2017. Developed by Bigfoot Biomedical, Bigfoot Unity is a smart insulin management system. It features connected insulin pen caps that use integrated continuous glucose monitoring (iCGM) data and healthcare provider instructions.

In April 2023, Cipla has signed a perpetual license agreement with Switzerland-based Novartis Pharma AG to manufacture and market Galvus and Galvus combination brands which are used in the treatment of type 2 diabetes from January 1, 2026.

Types Covered:

  • Norovirus
  • Rotavirus
  • Astrovirus
  • Enteric Adenovirus
  • Other Types

Diagnosis's Covered:

  • Physical Examination
  • Rapid Stool Test

Treatments Covered:

  • Intravenous Fluids
  • Antimotility Agents
  • Electrolytes
  • Antiemetic Drugs
  • Antidiarrheal Drugs
  • Other Treatments

Drugs Covered:

  • Antibiotics
  • Antacids
  • Laxatives
  • Chemotherapy Drugs
  • Other Drugs

Dosages Covered:

  • Tablet
  • Injection
  • Other Dosages

Indications Covered:

  • Watery Diarrhea
  • Vomiting
  • Abdominal Pain and Cramps
  • Dizziness
  • Diarrhea
  • Nausea
  • Vomiting
  • Headache
  • Chills
  • Loss of Appetite
  • Fever
  • Joint Stiffness
  • Sweating
  • Muscle Pain
  • Weight Loss
  • Other Indications

Route of Administrations Covered:

  • Oral
  • Intravenous
  • Others

Distribution Channels Covered:

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

End Users Covered:

  • Diagnostic Centers
  • Ambulatory Care Centers
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 End User Analysis
  • 3.7 Emerging Markets
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Viral Gastroenteritis Market, By Type

  • 5.1 Introduction
  • 5.2 Norovirus
  • 5.3 Rotavirus
  • 5.4 Astrovirus
  • 5.5 Enteric Adenovirus
  • 5.6 Other Types

6 Global Viral Gastroenteritis Market, By Diagnosis

  • 6.1 Introduction
  • 6.2 Physical Examination
  • 6.3 Rapid Stool Test

7 Global Viral Gastroenteritis Market, By Treatment

  • 7.1 Introduction
  • 7.2 Intravenous Fluids
  • 7.3 Antimotility Agents
  • 7.4 Electrolytes
  • 7.5 Antiemetic Drugs
  • 7.6 Antidiarrheal Drugs
  • 7.7 Other Treatments

8 Global Viral Gastroenteritis Market, By Drug

  • 8.1 Introduction
  • 8.2 Antibiotics
  • 8.3 Antacids
  • 8.4 Laxatives
  • 8.5 Chemotherapy Drugs
  • 8.6 Other Drugs

9 Global Viral Gastroenteritis Market, By Dosage

  • 9.1 Introduction
  • 9.2 Tablet
  • 9.3 Injection
  • 9.4 Other Dosages

10 Global Viral Gastroenteritis Market, By Indication

  • 10.1 Introduction
  • 10.2 Watery Diarrhea
  • 10.3 Vomiting
  • 10.4 Abdominal Pain and Cramps
  • 10.5 Dizziness
  • 10.6 Diarrhea
  • 10.7 Nausea
  • 10.8 Vomiting
  • 10.9 Headache
  • 10.10 Chills
  • 10.11 Loss of Appetite
  • 10.12 Fever
  • 10.13 Joint Stiffness
  • 10.14 Sweating
  • 10.15 Muscle Pain
  • 10.16 Weight Loss
  • 10.17 Other Indications

11 Global Viral Gastroenteritis Market, By Route of Administration

  • 11.1 Introduction
  • 11.2 Oral
  • 11.3 Intravenous
  • 11.4 Others

12 Global Viral Gastroenteritis Market, By Distribution Channel

  • 12.1 Introduction
  • 12.2 Hospital Pharmacy
  • 12.3 Retail Pharmacy
  • 12.4 Online Pharmacy

13 Global Viral Gastroenteritis Market, By End User

  • 13.1 Introduction
  • 13.2 Diagnostic Centers
  • 13.3 Ambulatory Care Centers
  • 13.4 Other End Users

14 Global Viral Gastroenteritis Market, By Geography

  • 14.1 Introduction
  • 14.2 North America
    • 14.2.1 US
    • 14.2.2 Canada
    • 14.2.3 Mexico
  • 14.3 Europe
    • 14.3.1 Germany
    • 14.3.2 UK
    • 14.3.3 Italy
    • 14.3.4 France
    • 14.3.5 Spain
    • 14.3.6 Rest of Europe
  • 14.4 Asia Pacific
    • 14.4.1 Japan
    • 14.4.2 China
    • 14.4.3 India
    • 14.4.4 Australia
    • 14.4.5 New Zealand
    • 14.4.6 South Korea
    • 14.4.7 Rest of Asia Pacific
  • 14.5 South America
    • 14.5.1 Argentina
    • 14.5.2 Brazil
    • 14.5.3 Chile
    • 14.5.4 Rest of South America
  • 14.6 Middle East & Africa
    • 14.6.1 Saudi Arabia
    • 14.6.2 UAE
    • 14.6.3 Qatar
    • 14.6.4 South Africa
    • 14.6.5 Rest of Middle East & Africa

15 Key Developments

  • 15.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 15.2 Acquisitions & Mergers
  • 15.3 New Product Launch
  • 15.4 Expansions
  • 15.5 Other Key Strategies

16 Company Profiling

  • 16.1 Bausch Health Companies Inc.
  • 16.2 Abbott
  • 16.3 Cipla Inc.
  • 16.4 Sanofi
  • 16.5 Bayer AG
  • 16.6 Allergan
  • 16.7 Dr. Reddy's Laboratories Ltd.
  • 16.8 Johnson & Johnson Private Ltd.
  • 16.9 Takeda Pharmaceutical Company Ltd.
  • 16.10 Valeant Pharmaceuticals
  • 16.11 Astellas Pharma Inc.
  • 16.12 Teva Pharmaceutical Industries Ltd.
  • 16.13 Sun Pharmaceutical Industries Ltd.
  • 16.14 Aurobindo Pharma
  • 16.15 Eli Lilly and Company
  • 16.16 Novartis AG
  • 16.17 Janssen Biotech Inc.
  • 16.18 Mylan N.V.

List of Tables

  • Table 1 Global Viral Gastroenteritis Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Viral Gastroenteritis Market Outlook, By Type (2021-2030) ($MN)
  • Table 3 Global Viral Gastroenteritis Market Outlook, By Norovirus (2021-2030) ($MN)
  • Table 4 Global Viral Gastroenteritis Market Outlook, By Rotavirus (2021-2030) ($MN)
  • Table 5 Global Viral Gastroenteritis Market Outlook, By Astrovirus (2021-2030) ($MN)
  • Table 6 Global Viral Gastroenteritis Market Outlook, By Enteric Adenovirus (2021-2030) ($MN)
  • Table 7 Global Viral Gastroenteritis Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 8 Global Viral Gastroenteritis Market Outlook, By Diagnosis (2021-2030) ($MN)
  • Table 9 Global Viral Gastroenteritis Market Outlook, By Physical Examination (2021-2030) ($MN)
  • Table 10 Global Viral Gastroenteritis Market Outlook, By Rapid Stool Test (2021-2030) ($MN)
  • Table 11 Global Viral Gastroenteritis Market Outlook, By Treatment (2021-2030) ($MN)
  • Table 12 Global Viral Gastroenteritis Market Outlook, By Intravenous Fluids (2021-2030) ($MN)
  • Table 13 Global Viral Gastroenteritis Market Outlook, By Antimotility Agents (2021-2030) ($MN)
  • Table 14 Global Viral Gastroenteritis Market Outlook, By Electrolytes (2021-2030) ($MN)
  • Table 15 Global Viral Gastroenteritis Market Outlook, By Antiemetic Drugs (2021-2030) ($MN)
  • Table 16 Global Viral Gastroenteritis Market Outlook, By Antidiarrheal Drugs (2021-2030) ($MN)
  • Table 17 Global Viral Gastroenteritis Market Outlook, By Other Treatments (2021-2030) ($MN)
  • Table 18 Global Viral Gastroenteritis Market Outlook, By Drug (2021-2030) ($MN)
  • Table 19 Global Viral Gastroenteritis Market Outlook, By Antibiotics (2021-2030) ($MN)
  • Table 20 Global Viral Gastroenteritis Market Outlook, By Antacids (2021-2030) ($MN)
  • Table 21 Global Viral Gastroenteritis Market Outlook, By Laxatives (2021-2030) ($MN)
  • Table 22 Global Viral Gastroenteritis Market Outlook, By Chemotherapy Drugs (2021-2030) ($MN)
  • Table 23 Global Viral Gastroenteritis Market Outlook, By Other Drugs (2021-2030) ($MN)
  • Table 24 Global Viral Gastroenteritis Market Outlook, By Dosage (2021-2030) ($MN)
  • Table 25 Global Viral Gastroenteritis Market Outlook, By Tablet (2021-2030) ($MN)
  • Table 26 Global Viral Gastroenteritis Market Outlook, By Injection (2021-2030) ($MN)
  • Table 27 Global Viral Gastroenteritis Market Outlook, By Other Dosages (2021-2030) ($MN)
  • Table 28 Global Viral Gastroenteritis Market Outlook, By Indication (2021-2030) ($MN)
  • Table 29 Global Viral Gastroenteritis Market Outlook, By Watery Diarrhea (2021-2030) ($MN)
  • Table 30 Global Viral Gastroenteritis Market Outlook, By Vomiting (2021-2030) ($MN)
  • Table 31 Global Viral Gastroenteritis Market Outlook, By Abdominal Pain and Cramps (2021-2030) ($MN)
  • Table 32 Global Viral Gastroenteritis Market Outlook, By Dizziness (2021-2030) ($MN)
  • Table 33 Global Viral Gastroenteritis Market Outlook, By Diarrhea (2021-2030) ($MN)
  • Table 34 Global Viral Gastroenteritis Market Outlook, By Nausea (2021-2030) ($MN)
  • Table 35 Global Viral Gastroenteritis Market Outlook, By Vomiting (2021-2030) ($MN)
  • Table 36 Global Viral Gastroenteritis Market Outlook, By Headache (2021-2030) ($MN)
  • Table 37 Global Viral Gastroenteritis Market Outlook, By Chills (2021-2030) ($MN)
  • Table 38 Global Viral Gastroenteritis Market Outlook, By Loss of Appetite (2021-2030) ($MN)
  • Table 39 Global Viral Gastroenteritis Market Outlook, By Fever (2021-2030) ($MN)
  • Table 40 Global Viral Gastroenteritis Market Outlook, By Joint Stiffness (2021-2030) ($MN)
  • Table 41 Global Viral Gastroenteritis Market Outlook, By Sweating (2021-2030) ($MN)
  • Table 42 Global Viral Gastroenteritis Market Outlook, By Muscle Pain (2021-2030) ($MN)
  • Table 43 Global Viral Gastroenteritis Market Outlook, By Weight Loss (2021-2030) ($MN)
  • Table 44 Global Viral Gastroenteritis Market Outlook, By Other Indications (2021-2030) ($MN)
  • Table 45 Global Viral Gastroenteritis Market Outlook, By Route of Administration (2021-2030) ($MN)
  • Table 46 Global Viral Gastroenteritis Market Outlook, By Oral (2021-2030) ($MN)
  • Table 47 Global Viral Gastroenteritis Market Outlook, By Intravenous (2021-2030) ($MN)
  • Table 48 Global Viral Gastroenteritis Market Outlook, By Others (2021-2030) ($MN)
  • Table 49 Global Viral Gastroenteritis Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 50 Global Viral Gastroenteritis Market Outlook, By Hospital Pharmacy (2021-2030) ($MN)
  • Table 51 Global Viral Gastroenteritis Market Outlook, By Retail Pharmacy (2021-2030) ($MN)
  • Table 52 Global Viral Gastroenteritis Market Outlook, By Online Pharmacy (2021-2030) ($MN)
  • Table 53 Global Viral Gastroenteritis Market Outlook, By End User (2021-2030) ($MN)
  • Table 54 Global Viral Gastroenteritis Market Outlook, By Diagnostic Centers (2021-2030) ($MN)
  • Table 55 Global Viral Gastroenteritis Market Outlook, By Ambulatory Care Centers (2021-2030) ($MN)
  • Table 56 Global Viral Gastroenteritis Market Outlook, By Other End Users (2021-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.